EGFR and non-small cell lung carcinoma: 47Sc-DTPA-cetuximab showed a binding pattern similar to that of cetuximab, and the cellular binding of radioimmunoconjugates in EGFR-overexpressing NSCLC cells correlated with EGFR expression levels (Fig. 4B).